Contemporary National Outcomes of Acute Myocardial Infarction-Cardiogenic Shock in Patients with Prior Chronic Kidney Disease and End-Stage Renal Disease

• Authors: Saraschandra Vallabhajosyula, Emory University; Lina Ya'Qoub, Louisiana State University; Vinayak Kumar, Mayo Clinic; Dhiran Verghese, Amita Health Saint Joseph Hospital; Anna V. Subramaniam, Mayo Clinic; Sri Harsha Patlolla, Mayo Clinic; Viral K. Desai, University of Louisville; Pranathi R. Sundaragiri, Mayo Clinic; Wisit Cheungpasitporn, Mayo Clinic; Abheshiek J. Deshmukh, Mayo Clinic; Kianoush Kashani, Mayo Clinic; Gregory W. Barsness, Mayo Clinic
• Journal Title: Journal of Clinical Medicine
• Volume: Volume 9, Number 11
• Publisher: MDPI AG | 2020
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.3390/jcm9113702
• Subjects: Health Sciences, Medicine and Surgery; Health Sciences, Health Care Management
• Keywords: acute myocardial infarction; cardiogenic shock; chronic kidney disease; end-stage renal disease; outcomes research

Abstract

Background: There are limited data on acute myocardial infarction with cardiogenic shock (AMI-CS) stratified by chronic kidney disease (CKD) stages. Objective: To assess clinical outcomes in AMI-CS stratified by CKD stages. Methods: A retrospective cohort of AMI-CS during 2005–2016 from the National Inpatient Sample was categorized as no CKD, CKD stage-III (CKD-III), CKD stage-IV (CKD-IV) and end-stage renal disease (ESRD). CKD-I/II were excluded. Outcomes included in-hospital mortality, use of coronary angiography, percutaneous coronary intervention (PCI) and mechanical circulatory support (MCS). We also evaluated acute kidney injury (AKI) and acute hemodialysis in non-ESRD admissions. Results: Of 372,412 AMI-CS admissions, CKD-III, CKD-IV and ESRD comprised 20,380 (5.5%), 7367 (2.0%) and 18,109 (4.9%), respectively. Admissions with CKD were, on average, older, of the White race, bearing Medicare insurance, of a lower socioeconomic stratum, with higher comorbidities, and higher rates of acute organ failure. Compared to the cohort without CKD, CKD-III, CKD-IV and ESRD had lower use of coronary angiography (72.7%, 67.1%, 56.9%, 61.1%), PCI (53.7%, 43.8%, 38.4%, 37.6%) and MCS (47.9%, 38.3%, 33.3%, 34.2%), respectively (all p < 0.001). AKI and acute hemodialysis use increased with increase in CKD stage (no CKD–38.5%, 2.6%; CKD-III–79.1%, 6.5%; CKD-IV–84.3%, 12.3%; p < 0.001). ESRD (adjusted odds ratio [OR] 1.25 [95% confidence interval {CI} 1.21–1.31]; p < 0.001), but not CKD-III (OR 0.72 [95% CI 0.69–0.75); p < 0.001) or CKD-IV (OR 0.82 [95 CI 0.77–0.87] was predictive of in-hospital mortality. Conclusions: CKD/ESRD is associated with lower use of evidence-based therapies. ESRD was an independent predictor of higher in-hospital mortality in AMI-CS.